chevron-down Created with Sketch Beta.
February 24, 2023

FDA Advisory Committee Unanimously Votes in Favor of Switching Narcan to Over-the-Counter Status

On February 15, 2023, a joint advisory committee made up of members of the Nonprescription Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee unanimously voted in favor of making the overdose-reversing drug Narcan (naloxone in the form of a prepackaged nasal spray) available over-the-counter. The only major issue the committee raised concerned some potentially confusing packaging, which the drug manufacturer said it would address. Advisory committee recommendations are not binding on the FDA, but the FDA usually follows them. A final decision from the FDA is expected by March 29, 2023.

The material in all ABA publications is copyrighted and may be reprinted by permission only. Request reprint permission here.